Drug Profile
Ataquimast
Alternative Names: F 11105; L 0066Latest Information Update: 21 Jul 2000
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Developer Pierre Fabre; University Hospital Ghent
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Immunomodulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 21 Jul 2000 L 0066 is now called Ataquimast
- 10 May 1999 Discontinued-I for Asthma in Belgium (PO)
- 10 May 1999 Discontinued-I for Asthma in France (PO)